genekam logo
  • usa
    • german
    • russia
    • china
Duissernstr. 65a · 47058 Duisburg · Germany
Tel. +49 203 / 555 858 -31 / 32 / 33 · Fax: +49 203 / 35 82 99
Latest News:

Genekam has developed novel corona virus 2020 (Wuhan strain specific) kits and potential therapeutic molecules.

Latest News:

3D Genomemedicine Inc is going to operate in USA

  • ++BREAKING NEWS (26.05.2020)++

    Plasma therapy accelerator (SARS-Hunter): a new solution for better antibody therapy for all coronavirus patients.

  • MEDICA 2021

    Visit us at MEDICA in Duesseldorf, Germany:
    15.11. - 18.11.21

  • BIO CEO & Investor Digital Conference

    Visit us at BIO CEO & Investor Digital Conference New York, USA:
    16.02. - 18.02.2021

  • INVEST 2021

    Visit us at INVEST in Stuttgart, Germany:
    23.03. - 24.04.21

  • LSX World Congress

    Visit us at LSX World Congress 2021 Virtual London, UK:
    01.02 - 05.02.2021

  • LSX Investival Showcase Virtual 2020

    Visit us at Investival Showcase Virtual London, UK:
    11.11. - 16.11.20

Production of human monoclonal antibodies

Mouse monoclonal antibodies have changed the face of immunology, but still there is a challenge to produce the human monoclonal antibodies as it is difficult to immunise the hman beings like mouse, therefore there is a need to develop in vitro immunisation methods of human B-lymphocytes. Peripheral blood is easily accessible source of B-lymphocytes, therefore Genekam Biotechnology AG has developed in vitro immunisation of B-lymphocytes of peripheral blood. Surely these methods can be used to in vitro immusiation of human B-lymphocytes of other sources like bone marrow, spleen, lymphnodes.

In vitro primary immunisation of human B-lymphocytes with different antigens e.g. viral, parasite bacterial antigens (primary immunisation): This technology offers a biggest advantage that one can immunise the lymphocytes with those antigens, which are toxic to human beings e.g. snake venom. This makes also possible to get the immunised lymphocytes against the diseases, which has been eradicated e.g. small pox or not present in one part of the world. One can do this method to get the immunised cells against the highly infectious agents, which are difficult to culture or there is a need to have high security laboratory. As we can stimulate the cells with killed (inactivated) agents. Therefore this method opens a new field to stimulate the lymphocytes against the new targets e.g. recently out broken swine flu H1N1 before it breaks out in vast way as this is happening at present. This method also opens a window to create entirely new antibodies, which are not known in the literature. This technology offers the possibility to create IgM antibodies too along with IgG production.

After immunisation, one can fuse the cell with cell lines as conventional hybridoma methods or one can go for genetechnological methods like cloning in E. coli for production of fragments of human antibodies. As modern methods like cell sorting are available now and they can be used to sort the specific B-lymphocytes for further immortalisation. Genekam In vitro immunisation methood can be used to create new kind of B-lymphocyte vaccines as instead of doing whole cell vaccine, one can administer only B-lymphocytes. The above said method s opening a new window to all laboratories in the world to do research to develop human monoclonal antibodies as well as to do more research on in vitro immunisation solutions.